Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Nov 2023: Trial registered, NCT06145373
  2. 1 Mar 2024: Trial started, NCT06145373

The trials

NCT06145373: A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

State
Under way
Phase
Phase 4
People
20 planned
Started
1 Mar 2024
Primary completion
28 May 2028
Arms
fitusiran
Results
None posted
  1. 24 Nov 2023: Trial registered
  2. 1 Mar 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.